New vaccine shows promise in training immune system to attack neuroendocrine tumors
NCT ID NCT03879694
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 28 times
Summary
This early-phase trial tested a vaccine called SurVaxM in 19 people with neuroendocrine tumors that had spread. The vaccine is designed to teach the body's immune cells to recognize and attack tumor cells. The main goal was to check for side effects and see if the vaccine could create an immune response against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ATYPICAL CARCINOID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.